Erasca (ERAS) Competitors $1.56 -0.05 (-3.11%) Closing price 04:00 PM EasternExtended Trading$1.55 -0.01 (-0.64%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. APGE, VCEL, BHVN, EWTX, AUPH, CDTX, PAHC, ARDX, TWST, and VERAShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Apogee Therapeutics (APGE), Vericel (VCEL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Apogee Therapeutics Vericel Biohaven Edgewise Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Erasca (NASDAQ:ERAS) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Does the media prefer ERAS or APGE? In the previous week, Apogee Therapeutics had 8 more articles in the media than Erasca. MarketBeat recorded 13 mentions for Apogee Therapeutics and 5 mentions for Erasca. Apogee Therapeutics' average media sentiment score of 1.21 beat Erasca's score of 1.12 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ERAS or APGE? Erasca presently has a consensus target price of $3.71, suggesting a potential upside of 138.10%. Apogee Therapeutics has a consensus target price of $97.29, suggesting a potential upside of 163.79%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is ERAS or APGE more profitable? Erasca's return on equity of -31.19% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% Apogee Therapeutics N/A -34.65%-32.76% Which has more risk and volatility, ERAS or APGE? Erasca has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Which has stronger valuation and earnings, ERAS or APGE? Apogee Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-3.47Apogee TherapeuticsN/AN/A-$182.15M-$4.13-8.93 Do insiders and institutionals hold more shares of ERAS or APGE? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 14.4% of Erasca shares are owned by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryApogee Therapeutics beats Erasca on 8 of the 13 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$442.53M$3.14B$5.81B$10.16BDividend YieldN/A2.32%5.69%4.60%P/E Ratio-3.4721.3674.6225.97Price / SalesN/A257.18454.4485.61Price / CashN/A45.3337.0859.91Price / Book1.049.6112.156.29Net Income-$161.65M-$53.29M$3.28B$270.77M7 Day Performance-3.11%0.36%0.98%3.32%1 Month PerformanceN/A8.98%7.19%6.40%1 Year Performance-49.02%13.18%63.14%28.24% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.5802 of 5 stars$1.56-3.1%$3.71+138.1%-47.6%$442.53MN/A-3.47120APGEApogee Therapeutics2.9176 of 5 stars$38.42+1.5%$97.29+153.2%-26.4%$1.75BN/A-9.3091News CoveragePositive NewsVCELVericel3.2132 of 5 stars$33.22-2.4%$60.40+81.8%-23.3%$1.72B$249.12M276.86300Positive NewsBHVNBiohaven3.2692 of 5 stars$14.50-8.7%$55.71+284.4%-60.4%$1.68BN/A-1.89239Trending NewsGap DownHigh Trading VolumeEWTXEdgewise Therapeutics2.8043 of 5 stars$14.88-4.4%$40.55+172.5%-12.9%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.9714 of 5 stars$12.30-0.8%$12.00-2.4%+95.7%$1.63B$235.13M28.61300News CoveragePositive NewsCDTXCidara Therapeutics3.2774 of 5 stars$62.15-1.6%$64.14+3.2%+458.3%$1.60B$1.27M-5.5890Positive NewsPAHCPhibro Animal Health4.5322 of 5 stars$39.43-0.1%$28.40-28.0%+101.4%$1.60B$1.30B33.422,475Trending NewsInsider TradeAnalyst RevisionARDXArdelyx4.6258 of 5 stars$6.59+1.1%$11.70+77.5%+12.1%$1.57B$333.61M-28.6590Positive NewsTWSTTwist Bioscience3.987 of 5 stars$26.25+1.9%$49.40+88.2%-42.3%$1.55B$312.97M-18.10990News CoverageVERAVera Therapeutics2.8554 of 5 stars$24.75+2.3%$63.00+154.5%-34.7%$1.54BN/A-6.9140Positive News Related Companies and Tools Related Companies Apogee Therapeutics Alternatives Vericel Alternatives Biohaven Alternatives Edgewise Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Cidara Therapeutics Alternatives Phibro Animal Health Alternatives Ardelyx Alternatives Twist Bioscience Alternatives Vera Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERAS Stock Alerts